Literature DB >> 11565583

Role of CMV in transplant coronary artery disease and survival after heart transplantation.

H A Valantine1.   

Abstract

The development of arteriosclerosis after heart transplantation plays a major role in decreased graft and patient survival. Although several pathogenic mechanisms have been proposed for the development of posttransplant coronary artery disease (CAD), a significant amount of accumulating evidence suggests that cytomegalovirus is a critical factor in this disease. Because post-transplant CAD is often a silent disease and early detection escapes conventional angiography, physicians must maintain close surveillance of heart transplant patients and institute prophylaxis in high-risk groups. In addition to targeting conventional risk factors, prophylaxis against CMV disease should decrease the incidence of the disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11565583

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  7 in total

1.  Evolving concepts and treatment strategies for cardiac allograft vasculopathy.

Authors:  Rodolfo Denadai Benatti; David O Taylor
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-01

Review 2.  Endothelial dysfunction and cardiac allograft vasculopathy.

Authors:  Monica Colvin-Adams; Nonyelum Harcourt; Daniel Duprez
Journal:  J Cardiovasc Transl Res       Date:  2012-11-08       Impact factor: 4.132

3.  Human cytomegalovirus downregulates expression of receptors for platelet-derived growth factor by smooth muscle cells.

Authors:  Sara Gredmark; Klas Strååt; Mohammed Homman-Loudiyi; Katja Kannisto; Cecilia Söderberg-Nauclér
Journal:  J Virol       Date:  2007-03-07       Impact factor: 5.103

4.  Differentiation Between Infection and Rejection in the Management of Cardiac Transplant Patients.

Authors:  Paul C. McGovern; Emily A. Blumberg
Journal:  Curr Infect Dis Rep       Date:  2001-08       Impact factor: 3.663

5.  Why CMV is a candidate for elimination and then eradication.

Authors:  Paul D Griffiths; Tabitha Mahungu
Journal:  J Virus Erad       Date:  2016-07-01

6.  Pharmacokinetics, Safety, and Tolerability of NPC-21, an Anti-Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo-Controlled, First-in-Human Phase 1 Study.

Authors:  Kenichi Furihata; Izumi Hamada; Takuro Niwa; Tatsuya Watanabe; Sachiko Ezoe
Journal:  Clin Pharmacol Drug Dev       Date:  2022-01-05

Review 7.  Regulatory and microbiological safety issues surrounding cell and tissue-engineering products.

Authors:  Daniel N Galbraith
Journal:  Biotechnol Appl Biochem       Date:  2004-08       Impact factor: 2.431

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.